teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12...1617181920212223242526...3132»
  • ||||||||||  ponesimod (ACT-128800) / J&J
    [VIRTUAL] Changes in Fatigue Status on the FSIQRMS Symptoms Domain in the Phase 3 OPTIMUM Study () -  Mar 6, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_380;    
    Independent of patient age, sex, concomitant antidepressant use, and disability, we conclude that no individual DMT is likely to contribute to the lessening or worsening of anxiety and/or depression symptoms in MS. For those patients with fatigue at baseline, a greater proportion improved their level of fatigue on the FSIQ-RMS-S by week 108 in the ponesimod 20mg arm than in the teriflunomide 14mg arm, particularly for those with more severe fatigue at baseline.
  • ||||||||||  ponesimod (ACT-128800) / J&J
    [VIRTUAL] A Central Effect of Ponesimod on Neuroinflammation in a PreClinical Model of Multiple Sclerosis () -  Mar 6, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_369;    
    Ponesimod prevented peripheral immune cell CNS infiltration and dampened glial activation leading to a lesser CNS neuroinflammation in the chronic EAE model. These results may provide clues on a possible central mechanism of action of ponesimod; further studies are warranted to dissect out a direct effect of ponesimod on glial S1P1 receptors versus an indirect effect due to reduced peripheral lymphocyte infiltrates in the brain.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] DiseaseModifying Therapies for the Treatment of RelapsingRemitting Multiple Sclerosis: A Comparison of Their Efficacy for Reducing Relapse Rate () -  Mar 6, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_225;    
    Although treatment responses varied, as well as comparators, the evaluated injectable, infused, and oral DMTs all provided a significant clinical benefit for relapse rate reduction. Innovations in the targeting/sequential monotherapy/escalation therapy/combination therapies towards the personalization of RRMS treatment will likely improve further the outcomes of patients with RRMS; future research in this regard is warranted in clinical trial and real-world settings.
  • ||||||||||  ponesimod (ACT-128800) / J&J
    [VIRTUAL] MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity () -  Mar 6, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_218;    
    Innovations in the targeting/sequential monotherapy/escalation therapy/combination therapies towards the personalization of RRMS treatment will likely improve further the outcomes of patients with RRMS; future research in this regard is warranted in clinical trial and real-world settings. Regardless of the EDA/NEDA status at week 108, ponesimod benefit over teriflunomide on MS-related fatigue remained the same, suggesting that addressing classical clinical efficacy (NEDA/EDA definition) might not be sufficient in addressing fatigue in RMS patients.
  • ||||||||||  teriflunomide / Generic mfg.
    [VIRTUAL] Changes in Peripheral Blood Cells with Teriflunomide and Treatment Response () -  Mar 6, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_197;    
    It was shown a significant decrease in leukocytes and lymphocytes in both groups and a lower increase in monocytes after 6 months. We did not find a statistically significant correlation between analytical values ​​and response to treatment.
  • ||||||||||  teriflunomide / Generic mfg., leflunomide / Generic mfg.
    Journal:  Selective Binding of Cyclodextrins with Leflunomide and Its Pharmacologically Active Metabolite Teriflunomide. (Pubmed Central) -  Mar 6, 2021   
    The interactions via hydrogen bonding are responsible for high negative enthalpy and entropy changes accompanying the complexation of cyclodextrins with teriflunomide. These results were in agreement with the molecular modeling calculations, which provide a clearer picture of the involved interactions at the atomic level.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Review, Journal:  Diagnosis and Treatment of Multiple Sclerosis: A Review. (Pubmed Central) -  Mar 3, 2021   
    One additional DMT, ocrelizumab, is approved for primary progressive MS...MS is characterized by physical disability, cognitive impairment, and other symptoms that affect quality of life. Treatment with DMT can reduce the annual relapse rate by 29% to 68% compared with placebo or active comparator.
  • ||||||||||  teriflunomide / Generic mfg.
    حبوب AUBAGIO؟ (Twitter) -  Feb 28, 2021   
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Review, Journal:  COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. (Pubmed Central) -  Feb 23, 2021   
    Available data suggest that teriflunomide therapy should not be discontinued in MS patients who develop SARS-CoV-2 infection, also in presence of significant comorbidities or clinical conditions requiring hospitalization. Additional studies are necessary to assess if the drug can also have a protective role against SARS-CoV-2.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    FDA event, Review, Journal:  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System. (Pubmed Central) -  Feb 20, 2021   
    Furthermore, we point to a possible common molecular effect of these drugs, namely a key role for NFκB signaling, causing a switch from pro-inflammatory microglia and astrocytes to anti-inflammatory phenotypes of these CNS cell types that recently emerged as central players in MS pathogenesis. This notion argues for the need to further explore the molecular mechanisms underlying MS drug action.
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), CPI-203 / Constellation
    Preclinical, Journal:  Accessing the transcriptional status of selenoproteins in skin cancer-derived cell lines. (Pubmed Central) -  Jan 26, 2021   
    Our results indicate that melanoma cells can modify, in a different manner, the selenoprotein transcript levels, as a possible mechanism to control tumor progression. We suggest that the usage of diet and supplements containing selenium should be carefully used for patients with melanoma.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Journal:  Ofatumumab (Kesimpta) for multiple sclerosis. (Pubmed Central) -  Jan 23, 2021   
    We suggest that the usage of diet and supplements containing selenium should be carefully used for patients with melanoma. No abstract available
  • ||||||||||  Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
    Trial completion, Trial completion date, Trial primary completion date:  ULTIMATE 2: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (clinicaltrials.gov) -  Jan 20, 2021   
    P3,  N=500, Completed, 
    Taken together, biotransformation of some DHODH inhibitor species may play a role in mediating or masking hepatic mitochondrial liabilities. Active, not recruiting --> Completed | Trial completion date: Sep 2021 --> Nov 2020 | Trial primary completion date: Mar 2021 --> Aug 2020
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Trial completion:  Teriflunomide Tecfidera LMCE (clinicaltrials.gov) -  Jan 6, 2021   
    P=N/A,  N=120, Completed, 
    The efficacy and safety of teriflunomide 14 mg was similar in all patients with relapsing MS, regardless of prior treatment history. Active, not recruiting --> Completed
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Review, Journal:  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. (Pubmed Central) -  Jan 2, 2021   
    However, they are associated with safety concerns and subsequent monitoring requirements. Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach.
  • ||||||||||  teriflunomide / Generic mfg.
    Clinical, Journal:  Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis. (Pubmed Central) -  Jan 2, 2021   
    In an advanced progressive multiple sclerosis population, no substantial differences in tolerability, safety, sustained EDSS progression, or sustained T25FW worsening over time were observed between glatiramer acetate and teriflunomide-treated groups. The small sample precluded definitive determination.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Zeposia (ozanimod) / BMS, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Ozanimod (Zeposia) for multiple sclerosis. (Pubmed Central) -  Dec 30, 2020   
    Therefore, hES-RPEs seem to have the ability to incur a broader range of RPE functions than ARPE-19 and should be more thoroughly explored for drug screening. No abstract available
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources. (Pubmed Central) -  Dec 23, 2020   
    In this retrospective study with longitudinal follow-up, we describe stratification of patients for face to face versus virtual visits in the absence of formal teleneurology, stratification of patients for treatment according to disease activity, rescheduling, deferring initiation or extending treatment intervals of certain disease modifying therapies(DMT's) or immunosuppressants(IS), especially those producing lymphocyte depletion in MS and the continuation of IS in patients with NMO/NMOSD. Furthermore, we highlight the use off-label treatments such as Intravenous immunoglobulins/rituximab,bridging interferons/Teriflunomide temporarily replacing more potent DMT choices,supply challenges of IS/DMT's and tailoring blood watches and neuroimaging surveillance based on the current health needs to stave off the pandemic and prevent at risk patients with iCNSID/health care workers from possibly being exposed to the COVID-19.
  • ||||||||||  brequinar (DUP 785) / BMS, Clear Creek Bio
    Journal:  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. (Pubmed Central) -  Dec 22, 2020   
    Our previously described brequinar analogue 41 was also synergistic with dipyridamole as were the FDA-approved DHODH inhibitors leflunomide and teriflunomide but the latter required much higher concentrations than brequinar. Therefore, a combination of brequinar and ENT inhibitors presents a potential anti-cancer strategy in select tumors.
  • ||||||||||  teriflunomide / Generic mfg., dutasteride / Generic mfg.
    Journal:  Substituent effects on the direct photolysis of benzotrifluoride derivatives. (Pubmed Central) -  Dec 16, 2020   
    In addition, flufenamic acid, travoprost, dutasteride, cyflumetofen, flutoanil, and teriflunomide were also examined, finding that their direct photochemical reactivity could be qualitatively predicted based on their ring substituents. We provide here a tool to evaluate the environmental persistence of benzotrifluoride contaminants, as well as to design more photodegradable new active ingredients.